ALEC:NSD-Alector Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 23.30

Change

0.00 (0.00)%

Market Cap

USD 1.88B

Volume

0.34M

Avg Analyst Target

USD 38.00 (+63.09%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California. Address: 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Company Website : http://www.alector.com

Address : 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Employees : 184

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.16

52 Week High : 39.74

Short Ratio : 8.76

52 Week Low : 9.12

Shorted Shares : 7,514,932

200 Day Moving Average : 23.47

Shorted Shares Previous Month : 6,787,086

50 Day Moving Average : 24.49

Shares Held By Insiders : 13.04%

Short Percentage : 9.00%

Shares Held by Institutions : 78.89%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

 USD130.87B 38.30 29.43
BNTX BioNTech SE

N/A

 USD60.07B 13.83 10.18
REGN Regeneron Pharmaceuticals Inc

N/A

 USD59.17B 9.99 7.57
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD47.16B 23.96 15.75
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BGNE BeiGene Ltd

N/A

 USD33.45B N/A N/A
SGEN Seagen Inc

N/A

 USD31.43B 53.89 40.74
GMAB Genmab A/S

N/A

 USD29.05B 74.91 8.12
ALNY Alnylam Pharmaceuticals Inc

N/A

 USD24.79B N/A N/A
RPRX Royalty Pharma plc

N/A

 USD23.31B 31.09 11.82

ETFs Containing ALEC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 54.00% 87% B+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.00% 87% B+ 87% B+
Trailing 12 Months  
Capital Gain 126.43% 89% B+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 126.43% 89% B+ 90% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.71% 44% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.71% 43% F 39% F
Risk Return Profile  
Volatility (Standard Deviation) 39.89% 74% C 46% F
Risk Adjusted Return 16.81% 44% F 31% F
Market Capitalization 1.88B 83% B 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 10.41 16% F 13% F
Price / Cash Flow Ratio -11.30 61% D- 73% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -78.62% 35% F 21% F
Return on Invested Capital -84.44% 25% F 9% F
Return on Assets -27.63% 45% F 13% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 8.76 23% F 12% F
Short Percent 14.12% 10% F 11% F
Beta 1.16 60% D- 48% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.